NCT00042783CompletedPhase 2
A Phase II Trial Of A D1/3-MAGE3-HIS Fusion Protein (NSC-719274) With Adjuvant SBAS02B (NSC-719275) For Patients With Stage IV, M1a or M1b Metastatic Melanoma
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- SWOG Cancer Research Network
- Locations
- 14
Study Overview
Brief Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Vaccine therapy may be effective in treating stage IV melanoma.
PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have stage IV melanoma.
Detailed Description
OBJECTIVES:
- Determine the feasibility of treating patients with stage IV melanoma with D1/3-MAGE-3-His fusion protein with SB-AS02B adjuvant.
- Determine the clinically confirmed response rates (partial and complete responses) of patients treated with this regimen.
- Determine the 6-month progression-free survival rate of patients treated with this regimen.
- Determine the qualitative and quantitative toxic effects of this regimen in these patients.
- Determine immune responses in patients treated with this regimen.
OUTLINE: This is a multicenter study.
Patients receive D1/3-MAGE-3-His fusion protein emulsified in SB-AS02B adjuvant intramuscularly once every 3 weeks for a total of 12 weeks (4 injections). In the absence of disease progression or unacceptable toxicity, patients receive a second 12-week course beginning at week 16.
Patients are followed every 3 months for 1 year and then every 6 months for 2 years.
Study Design
- Study Type
- Interventional
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Study Sites (14)
Loading locations...
Similar Trials
Unknown
Phase 1
Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV MelanomaMelanoma (Skin)NCT00010309Genzyme, a Sanofi Company
Unknown
Phase 2
Vaccine Therapy and Chemotherapy With or Without Tetanus Toxoid Compared With Chemotherapy Alone in Treating Patients With Metastatic Colorectal CancerColorectal CancerNCT00027833Herbert Irving Comprehensive Cancer Center
Terminated
Phase 2
Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Women With Locally Recurrent or Metastatic Breast CancerBreast CancerNCT00088985UNC Lineberger Comprehensive Cancer Center56
Terminated
Phase 2
Phase II Study of Allo LMI Vaccine With IL-2 for Stable Metastatic Breast CaBreast CancerNCT00784524Masonic Cancer Center, University of Minnesota14
Completed
Phase 2
Vaccine Therapy in Treating Patients With Metastatic Melanoma of the EyeExtraocular Extension MelanomaRecurrent Intraocular MelanomaNCT00020475National Cancer Institute (NCI)